Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia
[Protocol 11-002] |
Shukla, Neerav, MD |
Transplantation of Unrelated Donor Double-Unit Cord Blood with T-Cell-Depleted Stem Cells for Patients with High-Risk Hematologic Cancers
[Protocol 12-153] |
Barker, Juliet, MBBS |
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy
[Protocol 06-014] |
Barker, Juliet, MBBS |
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLA-Compatible Donor
[Protocol 12-053] |
O'Reilly, Richard, MD |
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
[Protocol 00-069] |
Offit, Kenneth, MD |
A Study of Posaconazole Versus Micafungin to Protect Against Invasive Fungal Infections in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome
[Protocol 10-038] |
Papanicolaou, Genovefa, MD |
A Study of Allogeneic Stem Cell Transplantation in HIV-Infected Patients with Hematologic Cancers
[Protocol 12-092] |
Sauter, Craig, MD |
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
[Protocol 08-087] |
Barker, Juliet, MBBS |
A Phase III Study of Sapacitabine in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia
[Protocol 12-034] |
Berman, Ellin, MD |
A Phase III Study of Rituximab plus GS-1101 (CAL-101) or Placebo for Previously Treated Chronic Lymphocytic Leukemia
[Protocol 12-160] |
Zelenetz, Andrew, MD, PhD |
A Phase III Study of Ponatinib versus Imatinib for Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
[Protocol 12-216] |
Berman, Ellin, MD |
A Phase III Study of Lenalidomide Alone and in Combination with Epoetin Alfa in Patients with Myelodysplastic Syndromes and Symptomatic Anemia
[Protocol 10-128] |
Klimek, Virginia, MD |
A Phase III Study of Elacytarabine versus Investigator's Choice in Patients with Late-Stage Acute Myeloid Leukemia
[Protocol 10-113] |
Douer, Dan, MD |
A Phase III Study of Cytarabine with or without Vosaroxin in Patients with First Relapsed or Refractory Acute Myeloid Leukemia
[Protocol 11-094] |
Klimek, Virginia, MD |
A Phase III Study of Clofarabine versus Standard Therapy for Newly Diagnosed Acute Myeloid Leukemia in Older Adults
[Protocol 12-059] |
Tallman, Martin, MD |
A Phase IIB Study of 5-Azacitidine with or without Panobinostat in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
[Protocol 12-219] |
Klimek, Virginia, MD |
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050] |
O'Reilly, Richard, MD |
A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
[Protocol 07-035] |
Hsu, Katharine, MD, PhD |
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia
[Protocol 08-031] |
Boulad, Farid, MD |
A Phase II Trial of a WT-1 Vaccine in Patients with Acute Myeloid Leukemia
[Protocol 10-143] |
Maslak, Peter, MD |
A Phase II Study of Vemurafenib in Patients with Relapsed or Refractory Hairy Cell Leukemia
[Protocol 12-200] |
Park, Jae, MD |
A Phase II Study of Tretinoin plus Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Therapy
[Protocol 11-040] |
Park, Jae, MD |
A Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia
[Protocol 11-024] |
Perales, Miguel-Angel, MD |
A Phase II Study of Quizartinib in Patients with FLT3-ITD-Positive Relapsed or Refractory Acute Myeloid Leukemia
[Protocol 12-106] |
Tallman, Martin, MD |
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS
[Protocol 08-008] |
Castro-Malaspina, Hugo, MD |
A Phase II Study of Palifermin with or without Leuprolide After T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-077] |
Goldberg, Jenna, MD |
A Phase II Study of KW-0761 or Standard Therapy in Patients with Previously Treated Adult T-Cell Leukemia-Lymphoma
[Protocol 12-251] |
Horwitz, Steven, MD |
A Phase II Study of Dasatinib in Children and Adolescents Newly Diagnosed with Chronic Phase CML or with Philadelphia Chromosome-Positive Leukemias Resistant to or Intolerant of Imatinib
[Protocol 11-030] |
Shukla, Neerav, MD |
A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 12-016] |
Giralt, Sergio, MD |
A Phase II Study of Blinatumomab in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
[Protocol 12-069] |
Douer, Dan, MD |
A Phase II Study of AUY922 in Patients with Myelofibrosis
[Protocol 12-076] |
Rampal, Raajit, MD |
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies
[Protocol 06-125] |
Boulad, Farid, MD |
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
[Protocol 95-024] |
O'Reilly, Richard, MD |
A Phase I/II Study of Low-Dose Cytarabine and Lintuzumab-Ac-225 in Older Patients with Previously Untreated Acute Myeloid Leukemia
[Protocol 09-053] |
Park, Jae, MD |
A Phase I/II Study of EPOCH Chemotherapy, Bortezomib, and Raltegravir for the Treatment of HTLV-1-Associated T-Cell Leukemia/Lymphoma
[Protocol 12-146] |
Noy, Ariela, MD |
A Phase I/II Study of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia in Complete Remission
[Protocol 12-229] |
Tallman, Martin, MD |
A Phase I/II Study of Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
[Protocol 05-103] |
Gerecitano, John, MD, PhD |
A Phase I Trial of NECTAR: Nelarabine, Etoposide, and Cyclophosphamide in Children with T-Cell Acute Lymphoblastic Leukemia
[Protocol 11-119] |
Trippett, Tanya, MD |
A Phase I Trial of B-Cell Acute Lymphoblastic Leukemia Treated with Autologous T Cells Gene-Targeted to the B-Cell Antigen CD19
[Protocol 09-114] |
Davila, Marco, MD, PhD |
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
[Protocol 07-055] |
O'Reilly, Richard, MD |
A Phase I Study of Tigecycline in Patients with Relapsed or Refractory Acute Myeloid Leukemia
[Protocol 12-148] |
Tallman, Martin, MD |
A Phase I Study of Plerixafor as a Chemosensitizing Agent for Children with Relapsed Acute Leukemia or Myelodysplastic Syndromes
[Protocol 11-208] |
Trippett, Tanya, MD |
A Phase I Study of Modified T Cells Targeted to CD19-Positive Acute Lymphoblastic Leukemia Relapsing After Allogeneic Stem Cell Transplantation
[Protocol 11-038] |
Kernan, Nancy, MD |
A Phase I Study of IPI-145 in Patients with Advanced Hematologic Cancers
[Protocol 12-088] |
Horwitz, Steven, MD |
A Phase I Study of Genetically Modified T Cells to Treat Recurrent or Refractory Chronic Lymphocytic Leukemia
[Protocol 06-138] |
Brentjens, Renier, MD, PhD |
A Phase I Study of EPZ-5676 in Patients with Relapsed/Refractory Leukemia and Other Advanced Hematologic Cancers
[Protocol 12-181] |
Tallman, Martin, MD |
A Phase I Study of Consolidation Therapy with Autologous T Cells Genetically Targeted to CD19 in Patients with Chronic Lymphocytic Leukemia After Initial Chemotherapy
[Protocol 11-048] |
Park, Jae, MD |
A Phase I Study of BMS-936558 in Patients with Relapsed or Refractory Hematologic Cancers
[Protocol 12-142] |
Lesokhin, Alexander, MD |
A Phase I Study of BMS-906024 in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma
[Protocol 11-181] |
Douer, Dan, MD |
A Phase I Study of Blinatumomab in Children and Adolescents with Relapsed/Refractory Acute Lymphoblastic Leukemia
[Protocol 12-044] |
Trippett, Tanya, MD |
